Actemra (tocilizumab) has long been one of the highest-revenue biologic drugs in rheumatology, generating billions in annual global sales for Genentech/Roche. For years, an Actemra biosimilar was something patients could only anticipate. That has changed: the FDA has now approved multiple tocilizumab biosimilars, offering meaningful potential cost relief for people treating rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions. This article is independent, educational information — FMHC is not affiliated with Genentech/Roche or any biosimilar manufacturer, and nothing here is medical advice.
What Is Actemra and What Does It Treat?
Actemra is a monoclonal antibody that blocks interleukin-6 (IL-6) receptors, inhibiting a key inflammatory pathway involved in multiple autoimmune and inflammatory conditions. The FDA first approved Actemra in January 2010 for moderate-to-severe rheumatoid arthritis in adults who had inadequate responses to other disease-modifying treatments.
Subsequent approvals expanded Actemra’s indications to include giant cell arteritis (2017), polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS). During the COVID-19 pandemic, Actemra received authorization (later a full approval) for certain hospitalized adults with severe COVID-19, based on evidence that IL-6 inhibition could reduce the risk of poor outcomes in severe cases.
Actemra is available in both intravenous and subcutaneous formulations. The IV formulation is administered on a schedule in a clinical setting, while the subcutaneous injection can be self-administered under a prescriber’s direction. Annual treatment costs for the brand can run roughly $20,000 to $36,000 or more depending on the formulation, dosing schedule, and indication — figures vary widely, so treat these as estimates and verify current pricing with your plan and pharmacy.
FDA-Approved Actemra Biosimilars Available Now
Biosimilar competition for tocilizumab has arrived. According to the FDA, the following tocilizumab biosimilars — all referencing Actemra — have been approved:
- Tofidence (tocilizumab-bavi) — approved September 2023, the first tocilizumab biosimilar in the US.
- Tyenne (tocilizumab-aazg) — approved March 2024, available in both intravenous and subcutaneous forms.
- Avtozma (tocilizumab-anoh) — approved January 2025.
Availability, formulations, and formulary placement can differ by product and by plan, and the biosimilar landscape continues to evolve, so verify what is currently approved and covered for your situation with the FDA’s resources and your prescriber. For a comprehensive overview of how this category works, see our article on what biosimilars are, and our comparison of biosimilar vs generic differences.
What “Biosimilar” Actually Means
A biosimilar is a biologic that the FDA has determined is highly similar to an already-approved reference product, with no clinically meaningful differences in safety, purity, and potency (efficacy). Biosimilars are not generics — biologics are large, complex molecules made in living cells, so an exact copy is not possible — but they go through a rigorous FDA approval pathway including extensive analytical characterization and clinical studies. The goal of biosimilars is to expand access and lower costs while maintaining the same standards of safety and effectiveness.
Interchangeability is a separate, additional FDA designation. An interchangeable biosimilar may, in some states and settings, be substituted at the pharmacy without the prescriber writing a new prescription. As of this update, the approved tocilizumab biosimilars are marketed as biosimilars; whether any has earned an interchangeability designation can change over time, so verify the current status with the FDA. Either way, switching between a reference biologic and a biosimilar is a clinical decision best made with your prescriber.
Actemra Patent Background
Roche and Genentech held multiple patents covering tocilizumab, including composition-of-matter, formulation, and method-of-use patents. As key patents expired and settlements were reached, the door opened for biosimilar approval and launch. Patent disputes between reference-product makers and biosimilar developers typically follow the “patent dance” process outlined in the Biologics Price Competition and Innovation Act (BPCIA), and settlement agreements often set specific launch dates. Understanding how drug patents work helps explain the timing of biosimilar competition.
Expected Cost Savings from Actemra Biosimilars
Based on experience from other biosimilar markets, patients and the healthcare system can expect meaningful cost reductions as Actemra biosimilar competition matures. Initial biosimilar launches commonly offer discounts in the range of 15 to 35 percent off the reference product’s price, with deeper discounts developing as additional competitors enter and payers negotiate.
The biosimilar Humira market provides an instructive precedent: adalimumab biosimilar prices eventually fell substantially as competition intensified. The tocilizumab market may follow a different trajectory depending on the number of competitors, formulary decisions, and payer dynamics, but savings are anticipated. For a patient paying around $30,000 per year, even a 30 percent reduction would be roughly $9,000 in annual savings — and the impact can be larger for patients whose coinsurance is calculated as a percentage of the drug’s list price. Price-comparison tools like GoodRx and your plan’s cost-estimator can help you compare options, though specialty biologics are usually filled through specialty pharmacies rather than at retail.
Safety Considerations for Tocilizumab and Its Biosimilars
Because a biosimilar has no clinically meaningful differences from its reference product, tocilizumab’s known safety considerations apply equally to Actemra and its biosimilars. Tocilizumab carries an FDA boxed warning about the risk of serious infections (including tuberculosis, bacterial, invasive fungal, and other opportunistic infections) that can lead to hospitalization or death. Other monitored effects include elevated liver enzymes, changes in lipid levels, gastrointestinal perforation risk, and reduced neutrophil and platelet counts. Patients are screened and monitored before and during treatment — this is not a self-managed medication, and it should be taken only under the supervision of a qualified clinician.
One particular clinical nuance: tocilizumab suppresses C-reactive protein (CRP), a common inflammation marker, so it can mask the usual signs of an infection. This effect applies to the reference product and biosimilars alike and is a reason clinicians monitor patients closely rather than a difference between products. Post-marketing surveillance continues after approval to track long-term safety.
How Biosimilar Competition Affects the IL-6 Inhibitor Market
Actemra is not the only IL-6 pathway inhibitor available. Kevzara (sarilumab), developed by Sanofi and Regeneron, targets the IL-6 receptor through a different antibody. The competitive dynamics between tocilizumab biosimilars and brand alternatives will influence pricing, formulary placement, and prescribing patterns across the entire IL-6 inhibitor category.
Payers and pharmacy benefit managers (PBMs) evaluate the relative value of biosimilar tocilizumab against other options, weighing clinical evidence and cost. This competition can drive down costs across the category and expand access for patients who might otherwise struggle to afford IL-6 inhibitor therapy.
Preparing to Discuss Biosimilars With Your Care Team
If you currently take Actemra or are starting IL-6 inhibitor therapy, planning ahead can help you take advantage of biosimilar options. Discuss biosimilar readiness with your rheumatologist or prescriber — they can explain the clinical evidence and whether a specific biosimilar is appropriate for you. Starting on, or switching to, a biosimilar is a clinical decision, not something to arrange on your own.
Contact your insurance provider to understand how your plan handles biosimilar formulary placement. Many payers favor biosimilars through preferred-tier placement, step therapy, or financial incentives, and some plans may prefer a particular product. Knowing your plan’s approach in advance helps you prepare for potential formulary changes and avoid surprises at the specialty pharmacy.
Frequently Asked Questions
Are Actemra biosimilars available now?
Yes. The FDA has approved multiple tocilizumab biosimilars — Tofidence (2023), Tyenne (2024), and Avtozma (2025). Availability, formulations, and coverage vary by product and plan, so confirm current options with your prescriber and specialty pharmacy.
Will an Actemra biosimilar work the same way?
An FDA-approved biosimilar must demonstrate no clinically meaningful differences from the reference product in safety, efficacy, and immunogenicity. Clinical studies for tocilizumab biosimilars are designed to confirm equivalent performance in conditions like rheumatoid arthritis. For how biosimilars differ from generics, see our guide on biosimilar vs generic differences.
Can I switch from Actemra to a biosimilar mid-treatment?
Only with your prescriber’s guidance. Switching studies across many biologics have generally shown that transitioning from a reference product to a biosimilar does not increase adverse events or reduce efficacy, but your physician should evaluate your disease stability, coverage, and treatment response before recommending a switch.
Are the biosimilars “interchangeable” with Actemra?
Interchangeability is a separate FDA designation from being a biosimilar, and it can determine whether a pharmacist may substitute without a new prescription in some states. The designation status can change over time, so verify the current status with the FDA and rely on your prescriber’s direction.
Will both IV and subcutaneous biosimilars be available?
It depends on the product. Some tocilizumab biosimilars offer both intravenous and subcutaneous forms while others may launch with one. Ask your physician which formulations are approved and available for your situation.
Looking Ahead at Tocilizumab Affordability
The arrival of FDA-approved Actemra biosimilar alternatives marks a real step toward more affordable IL-6 inhibitor therapy. For patients managing chronic inflammatory conditions, biosimilar competition could reduce annual treatment costs by thousands of dollars. Stay engaged with your healthcare team, confirm current approvals and coverage through FDA.gov, and explore all available options for managing your healthcare costs as the competitive landscape continues to evolve.
TL;DR: Actemra (tocilizumab) biosimilars are now FDA-approved and available — Tofidence, Tyenne, and Avtozma — and can lower costs while meeting the same FDA standards for safety and effectiveness. Starting or switching to a biosimilar, and any interchangeable substitution, is a clinical decision made with your prescriber. Tocilizumab requires monitoring (including for serious infections) and is not self-managed.
Medical disclaimer: This article is independent, educational information and not medical advice. FMHC is not affiliated with Genentech/Roche or any biosimilar manufacturer. Approvals, interchangeability status, and prices change — verify current details with the FDA and your care team, and make treatment decisions with your prescriber.
Sources
- U.S. Food & Drug Administration — Biosimilar Product Information (approved tocilizumab biosimilars: Tofidence, Tyenne, Avtozma)
- FDA — Biosimilar and Interchangeable Biologics: More Treatment Choices
- FDA — Purple Book (licensed biological products database)
- MedlinePlus (U.S. National Library of Medicine) — Tocilizumab Injection